Predictive Oncology’s (POAI) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Predictive Oncology (NASDAQ:POAI)‘s stock had its “sell (e+)” rating reissued by research analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Predictive Oncology Stock Down 5.5%

Shares of Predictive Oncology stock opened at $8.01 on Friday. Predictive Oncology has a 12 month low of $8.01 and a 12 month high of $45.90. The business has a fifty day simple moving average of $13.58 and a 200 day simple moving average of $13.68. The stock has a market cap of $6.09 million, a PE ratio of -0.39 and a beta of 1.32.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings data on Wednesday, August 13th. The medical instruments supplier reported ($3.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($1.95). Predictive Oncology had a negative return on equity of 722.01% and a negative net margin of 587.31%.The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $1.50 million. Analysts expect that Predictive Oncology will post -2.08 EPS for the current fiscal year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.